Hemideina has raised funds via a private placement
Hemideina has raised US$7.4 million. The capital raised will be used to fund product development in preparation for the first human studies.
Hemideina is a Melbourne-based private company that is set to disrupt the cochlear implant market through its proprietary mechanical signal processing technology, the Hera wireless implant system. The company aims to provide a paradigm shift in hearing implant performance that will lead to increased access and adoption of treatment.
Oaklins’ team in Australia acted as lead manager in this transaction. The team has assisted Hemideina with fundraising since 2018 and is proud to support them on their mission to positively impact the lives of people with severe-to-profound hearing loss.



Elizabeth Williams
CEO and Co-founder, Hemideina
Talk to the deal team


Related deals
SulAmérica and Rede D’Or São Luiz have announced a combination
SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.
Learn moreCAPSA has been acquired by Acrotec SA
The private owners of CAPSA – Camille Piquerez SA (CAPSA) have sold the company to Acrotec SA, a portfolio company of Carlyle Group.
Learn moreLonia has been acquired by Studenac
The private shareholder of Lonia has sold the company to Studenac.
Learn more